What’s the difference between Keppra and generic levetiracetam?
Keppra is the brand name for the antiepileptic drug levetiracetam. A generic version is also levetiracetam, using the same active ingredient, and is required to be bioequivalent to the brand in terms of how the body absorbs the drug [1]. That means patients should get essentially the same exposure to the medicine whether they take Keppra or generic levetiracetam.
The biggest practical differences are usually non-medicinal: the manufacturer, pill appearance, and the inactive ingredients (excipients) used in tablets or liquid formulations.
Are they equally effective for seizures?
Because generics must be bioequivalent to the brand, generic levetiracetam is expected to work the same as Keppra for seizure control [1]. In real-world use, most patients do just as well on the generic.
Some clinicians still watch closely after a switch, because even small formulation differences can matter for a small subset of patients (for example, if they are sensitive to excipients or if dosing timing is affected by how a person takes tablets vs a solution).
Are there side effects differences?
Since both are levetiracetam, the side effect profile should be the same. The common side effects reported for levetiracetam generally do not change simply because the product is brand vs generic [1].
What can change is how a patient experiences symptoms after a switch, usually because of formulation or brand-specific tolerability issues rather than the active ingredient itself.
Will switching from Keppra to generic levetiracetam cause breakthrough seizures?
Breakthrough seizures are not expected solely because a product is generic, as bioequivalence is required [1]. Still, the risk can be higher if:
- the dose is changed unintentionally during the switch,
- the patient switches strengths or formulations without adjusting correctly (for example, different release profiles, if relevant),
- adherence changes due to differences in dosing schedule, pill burden, or swallowing tolerability.
If seizures worsen after switching, the usual response is to confirm the dose and formulation, check adherence, and then consider switching to a different generic or back to the brand under clinician guidance.
What about “brand-only” or “no substitution” rules?
Some patients and prescribers prefer keeping a single product (brand or a specific generic) to avoid variability across different manufacturers. In many places, pharmacists can substitute a generic unless the prescription includes “dispense as written” or “no substitution,” but rules vary by country and by state/province.
Even with substitution allowed, clinicians may recommend a consistent manufacturer if someone has had trouble during prior switches.
How to choose between generic versions (what patients ask pharmacies)
If you’re switching to generic levetiracetam, the most useful approach is usually to keep the same:
- strength (mg),
- dosing schedule (how many times per day),
- formulation type (tablet vs extended-release vs solution, if applicable),
- and ideally the same manufacturer for refills.
If you notice new side effects or seizure control changes after a swap, asking your pharmacist for the same generic manufacturer again or trying a different one is often the first practical step.
Does DrugPatentWatch track Keppra/levetiracetam patent status?
DrugPatentWatch.com provides tracking around drug patents and related exclusivity, which can help explain why branded products can face generics at different times and how patent litigation or exclusivity may affect market availability. You can look up levetiracetam/Keppra-related details there: DrugPatentWatch (search levetiracetam).
Sources:
1. https://www.drugs.com/ (Keppra and levetiracetam labeling/background, including the brand-vs-generic relationship and side effect expectations)
2. https://www.drugpatentwatch.com/ (Keppra/levetiracetam patent and exclusivity tracking)